For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Recurrent Glioblastoma Patients | Nivolumab: OPDIVO is a human programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. BMS-986016: Anti-Lymphocyte Activation Gene-3 antibody undergoing clinical evaluation by Bristol-Myers Squibb | 13 | None | 13 | 13 | 1 | 13 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Death | SYSTEMATIC_ASSESSMENT | General disorders | None | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Lymphocyte count decreased | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | None | View |
| White blood cell decreased | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | None | View |
| Thrombocytosis | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | None | View |
| Neutrophil count decreased | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | None | View |
| Thrombocytopenia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | None | View |
| Elevated WBC count | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | None | View |
| Anemia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | None | View |
| ALC low | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | None | View |
| Hypothyroidism | SYSTEMATIC_ASSESSMENT | Endocrine disorders | None | View |
| Hyperglycemia | SYSTEMATIC_ASSESSMENT | Endocrine disorders | None | View |
| Abnormal thyroid function tests | SYSTEMATIC_ASSESSMENT | Endocrine disorders | None | View |
| Cushingoid | SYSTEMATIC_ASSESSMENT | Endocrine disorders | None | View |
| Adrenal insufficiency | SYSTEMATIC_ASSESSMENT | Endocrine disorders | None | View |
| Hypokalemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | None | View |
| Hypocalcemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | None | View |
| Hypoalbuminemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | None | View |
| Hyperglycemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | None | View |
| Alkalosis | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | None | View |
| Lymphocyte count decreased | SYSTEMATIC_ASSESSMENT | Investigations | None | View |
| Investigations - Other specify | SYSTEMATIC_ASSESSMENT | Investigations | None | View |
| GGT increased | SYSTEMATIC_ASSESSMENT | Investigations | None | View |
| CK increased | SYSTEMATIC_ASSESSMENT | Investigations | None | View |
| elevated total bilirubin | SYSTEMATIC_ASSESSMENT | Investigations | None | View |
| elevated AST | SYSTEMATIC_ASSESSMENT | Investigations | None | View |
| Alkaline phosphatase increased | SYSTEMATIC_ASSESSMENT | Investigations | None | View |
| Alanine aminotransferase increased | SYSTEMATIC_ASSESSMENT | Investigations | None | View |
| Fever | SYSTEMATIC_ASSESSMENT | General disorders | None | View |
| Fatigue | SYSTEMATIC_ASSESSMENT | General disorders | None | View |
| Chills | SYSTEMATIC_ASSESSMENT | General disorders | None | View |
| Vomiting | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | None | View |
| Nausea | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | None | View |
| Hemorrhoids | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | None | View |
| Fecal incontinence | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | None | View |
| Diarrhea | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | None | View |
| Constipation | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | None | View |
| Anorectal infection | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | None | View |
| Blurred Vision | SYSTEMATIC_ASSESSMENT | Eye disorders | None | View |
| Vertigo | SYSTEMATIC_ASSESSMENT | Ear and labyrinth disorders | None | View |
| atrial fibrillation | SYSTEMATIC_ASSESSMENT | Cardiac disorders | None | View |
| Hypertension | SYSTEMATIC_ASSESSMENT | Cardiac disorders | None | View |
| Li Fraumeni Syndrome | SYSTEMATIC_ASSESSMENT | Congenital, familial and genetic disorders | None | View |
| Upper respiratory infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | None | View |
| Fall | SYSTEMATIC_ASSESSMENT | Injury, poisoning and procedural complications | None | View |
| Wound dehisence of biopsy site | SYSTEMATIC_ASSESSMENT | Injury, poisoning and procedural complications | None | View |
| extremity weakness | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | None | View |
| Glioblastoma | SYSTEMATIC_ASSESSMENT | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | None | View |
| Insomnia | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | None | View |
| Urinary Incontinence | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | None | View |
| urinary urgency | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | None | View |
| benign prostate hypertrophy | SYSTEMATIC_ASSESSMENT | Reproductive system and breast disorders | None | View |
| Flushing | SYSTEMATIC_ASSESSMENT | Vascular disorders | None | View |
| Hypertension | SYSTEMATIC_ASSESSMENT | Vascular disorders | None | View |
| Skin and subcutaneous tissue disorders - Other, specify - limited skin erythema only, asymptomatic | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | None | View |
| pruritis | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | None | View |
| Petechial rash | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | None | View |
| Macular rash | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | None | View |
| Papular erythematous rash on upper extremities | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | None | View |
| Folliculitis | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | None | View |
| rash | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | None | View |
| Pityrosporum folliculitis | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | None | View |
| sweating | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | None | View |
| sore throat | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | None | View |
| Cough | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | None | View |
| Congestion | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | None | View |
| Rhinorrhea | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | None | View |
| Atelectasis | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | None | View |
| balance instability | SYSTEMATIC_ASSESSMENT | Nervous system disorders | None | View |
| Cerebral edema | SYSTEMATIC_ASSESSMENT | Nervous system disorders | None | View |
| change with cognition "fuzzy cognition | SYSTEMATIC_ASSESSMENT | Nervous system disorders | None | View |
| Communicating hydrocephalus | SYSTEMATIC_ASSESSMENT | Nervous system disorders | None | View |
| Difficulty reading | SYSTEMATIC_ASSESSMENT | Nervous system disorders | None | View |
| Drowsiness | SYSTEMATIC_ASSESSMENT | Nervous system disorders | None | View |
| dysphasia | SYSTEMATIC_ASSESSMENT | Nervous system disorders | None | View |
| Edema, cerebral | SYSTEMATIC_ASSESSMENT | Nervous system disorders | None | View |
| Headache | SYSTEMATIC_ASSESSMENT | Nervous system disorders | None | View |
| intracranial edema | SYSTEMATIC_ASSESSMENT | Nervous system disorders | None | View |
| Intracranial Hemorrhage (CT) | SYSTEMATIC_ASSESSMENT | Nervous system disorders | None | View |
| Left facial droop | SYSTEMATIC_ASSESSMENT | Nervous system disorders | None | View |
| left facial weakness | SYSTEMATIC_ASSESSMENT | Nervous system disorders | None | View |
| left hemiparesis | SYSTEMATIC_ASSESSMENT | Nervous system disorders | None | View |
| Left lower quadrantanopsia | SYSTEMATIC_ASSESSMENT | Nervous system disorders | None | View |
| Left superior quadrantanopsia | SYSTEMATIC_ASSESSMENT | Nervous system disorders | None | View |
| Mental Fogginess- distraction | SYSTEMATIC_ASSESSMENT | Nervous system disorders | None | View |
| Paresthesia | SYSTEMATIC_ASSESSMENT | Nervous system disorders | None | View |
| Photophobia | SYSTEMATIC_ASSESSMENT | Nervous system disorders | None | View |
| Positive pronator drift test | SYSTEMATIC_ASSESSMENT | Nervous system disorders | None | View |
| Pre-syncope | SYSTEMATIC_ASSESSMENT | Nervous system disorders | None | View |
| Facial muscle weakness | SYSTEMATIC_ASSESSMENT | Nervous system disorders | None | View |
| Seizure | SYSTEMATIC_ASSESSMENT | Nervous system disorders | None | View |
| Short term memory difficulty | SYSTEMATIC_ASSESSMENT | Nervous system disorders | None | View |
| Somnolence | SYSTEMATIC_ASSESSMENT | Nervous system disorders | None | View |
| Stroke | SYSTEMATIC_ASSESSMENT | Nervous system disorders | None | View |